Literature DB >> 15949823

Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus.

Kevin M Gamber1, Heather Macarthur, Thomas C Westfall.   

Abstract

Little is known about the mechanism of action behind the orexigenic activity of cannabinoids. Neuropeptide Y (NPY) is one of the most potent orexigenic factors and is a key mediator in the hypothalamic control of food intake. We examined the effect of cannabinoids on NPY release using a rat hypothalamic explant model. The cannabinoid agonists anandamide (AEA) and CP55,940 both significantly augmented resting and KCl-evoked NPY release. AM251, a cannabinoid receptor antagonist, blocked the augmentation of NPY release elicited by AEA and CP55,940. Additionally, AM251 administered alone, in the absence of exogenous cannabinoid agonists, inhibited NPY release demonstrating the role of endogenous cannabinoids in NPY release. Combined, these findings demonstrate that cannabinoids augment NPY release in the hypothalamus and that this may be a potential mechanism behind the orexigenic activity of cannabinoids.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15949823     DOI: 10.1016/j.neuropharm.2005.04.017

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  31 in total

1.  Role of cannabinoidergic system on food intake in neonatal layer-type chicken.

Authors:  Abbas Alizadeh; Morteza Zendehdel; Vahab Babapour; Saeed Charkhkar; Shahin Hassanpour
Journal:  Vet Res Commun       Date:  2015-04-23       Impact factor: 2.459

Review 2.  Neuropeptide Y in normal eating and in genetic and dietary-induced obesity.

Authors:  B Beck
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

3.  FAAH deficiency promotes energy storage and enhances the motivation for food.

Authors:  C Touriño; F Oveisi; J Lockney; D Piomelli; R Maldonado
Journal:  Int J Obes (Lond)       Date:  2009-12-22       Impact factor: 5.095

Review 4.  Stress Cardiomyopathy Diagnosis and Treatment: JACC State-of-the-Art Review.

Authors:  Horacio Medina de Chazal; Marco Giuseppe Del Buono; Lori Keyser-Marcus; Liangsuo Ma; F Gerard Moeller; Daniel Berrocal; Antonio Abbate
Journal:  J Am Coll Cardiol       Date:  2018-10-16       Impact factor: 24.094

Review 5.  Endocannabinoid signalling: has it got rhythm?

Authors:  Linda K Vaughn; Gerene Denning; Kara L Stuhr; Harriet de Wit; Matthew N Hill; Cecilia J Hillard
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 6.  Physical activity and the endocannabinoid system: an overview.

Authors:  Mirko Tantimonaco; Roberta Ceci; Stefania Sabatini; Maria Valeria Catani; Antonello Rossi; Valeria Gasperi; Mauro Maccarrone
Journal:  Cell Mol Life Sci       Date:  2014-02-14       Impact factor: 9.261

Review 7.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 8.  Cannabinoids in eating disorders and obesity.

Authors:  Francisco Arias Horcajadas
Journal:  Mol Neurobiol       Date:  2007-07-07       Impact factor: 5.590

9.  Leptin-dependent control of glucose balance and locomotor activity by POMC neurons.

Authors:  Lihong Huo; Kevin Gamber; Sarah Greeley; Jose Silva; Nicholas Huntoon; Xing-Hong Leng; Christian Bjørbaek
Journal:  Cell Metab       Date:  2009-06       Impact factor: 27.287

Review 10.  Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists.

Authors:  Helen Butler; Márta Korbonits
Journal:  Eur J Endocrinol       Date:  2009-09-03       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.